MIRA Pharmaceuticals Introduces Ketamir-2 as a Promising Pain Relief Alternative

MIRA Pharmaceuticals has announced that its new oral ketamine analog, Ketamir-2, showed superior pain relief in preclinical studies compared to Gabapentin and Pregabalin. This development highlights Ketamir-2 as a potential alternative for neuropathic pain patients, offering effective relief without the risks associated with opioid use.

The study demonstrated that Ketamir-2 surpassed the effectiveness of Pregabalin by 112% and Gabapentin by 70% at higher doses. Unlike its counterparts, Ketamir-2 presents fewer cognitive side effects and no risk of dependence, making it safer for long-term use.

Given the increasing global concern for neuropathic pain, MIRA aims to submit an Investigational New Drug application by year-end, with Phase 1 clinical trials set for early 2025. The company is also exploring Ketamir-2’s potential for treating PTSD and other neuropsychiatric disorders, seeking government grants to accelerate its development.